Conformal is focused on reducing strokes in patients with atrial fibrillation.
We are guided by the principle that left atrial appendage closure provides an important alternative to long-term oral anticoagulation, a strategy without long-term bleeding side effects or daily medications.
To advance left atrial appendage closure (LAAC) to a first-line strategy for stroke prevention by simplifying the procedure, improving the implant and delivery system, and eliminating the need for general anesthesia.
Large Addressable Market
About 6 million people in the United States are affected by atrial fibrillation. Of those, 64.5% are recommended for oral anticoagulants to reduce their risk of Afib-associated stroke. However, 12.5% are contraindicated for oral anticoagulants. As a result, the addressable market for left atrial appendage closure is over 700,000 patients.
Facts and Figures
About 33 million people globally are affected by atrial fibrillation. These people are five times more likely to experience stroke than the general population, and 90% of the clots leading to these strokes form in the left atrial appendage. The annual cost to treat atrial fibrillation in the United States is about $6 billion.
33 million people globally are affected by atrial fibrillation (Afib)4
Afib patients are 5x more likely to experience stroke than the general population5,6
In people with Afib, more than 90% of clots that lead to stroke form in the left atrial appendage7
The annual cost of Afib treatment to the US healthcare system8